{
    "clinical_study": {
        "@rank": "129388", 
        "arm_group": {
            "arm_group_label": "POL6326", 
            "arm_group_type": "Experimental", 
            "description": "2-hour single intravenous infusion doses of POL6326"
        }, 
        "brief_summary": {
            "textblock": "Phase I study to determine and compare the safety/tolerability of single ascending doses of\n      POL6326 by intravenous infusion."
        }, 
        "brief_title": "Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Phase I Study\n\n        -  to determine and compare the safety of single ascending doses of POL6326 by intravenous\n           infusion\n\n        -  to determine the relationship between 2-hour single intravenous infusion doses of\n           POL6326 and the concentration of HSC and mature WBC in peripheral blood using\n           immunophenotypic assays."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Mobilization and collection of hematopoietic stem cells (HSCs) using G-CSF at least 6\n             weeks but less than 6 months prior to protocol enrollment.\n\n          2. Ages greater than or equal to 18 years and less than or equal to 55 years.\n\n          3. Normal liver and renal function, normal CBC, normal ECG, normal blood pressure\n             including adequately medically controlled idiopathic arterial hypertension, no other\n             contraindications to mobilized peripheral blood stem cell donation according to WMDA\n             criteria and relevant SOPs at the study site defining additional exclusion criteria\n             for stem cell donation.\n\n          4. Subject must be eligible for normal blood donation according to requirements for IDMs\n             as laid out by national law for blood donors.\n\n          5. Ability to comprehend the investigational nature of the study and provide informed\n             consent.\n\n        Exclusion Criteria:\n\n          1. Active infection or history of recurrent infection- hepatitis B and C (HBsAg,\n             Anti-HBc, Anti-HCV), HIV and HTLV-1.\n\n          2. History of autoimmune disease such as rheumatoid arthritis, systemic lupus\n             erythematous.\n\n          3. History of cancer within the past 5 years excluding basal cell or squamous cell\n             carcinoma of the skin.\n\n          4. History of any hematologic disorders including thromboembolic disease.\n\n          5. History of cardiac disease such as uncontrolled hypertension, peripheral vascular\n             disease, myocardial infarction, cardiac arrhythmias OR related symptoms such as\n             tachycardia, chest pain, shortness of breath which have required medical intervention\n             OR treatment or a Framingham coronary disease risk prediction score of greater than\n             10% 10 year coronary heart disease (CHD) risk."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841476", 
            "org_study_id": "POL-3"
        }, 
        "intervention": {
            "arm_group_label": "POL6326", 
            "intervention_name": "POL6326", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peripheral blood", 
            "HSC", 
            "Mobilization", 
            "CXCR4", 
            "volunteers"
        ], 
        "lastchanged_date": "April 23, 2013", 
        "location": {
            "contact": {
                "email": "h.boenig@blutspende.de", 
                "last_name": "Boenig"
            }, 
            "facility": {
                "address": {
                    "city": "Frankfurt", 
                    "country": "Germany", 
                    "zip": "60590"
                }, 
                "name": "German Red Cross Blood Service and Institute for Transfusion Medicine and Immunohematology of the Goethe University"
            }, 
            "investigator": {
                "last_name": "Halvard Boenig, M.D. Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "POL6326 - A Phase I, Open, Single Intravenous Infusion Dose, Pharmacokinetic and Pharmacodynamic Study in Healthy Volunteers Who Are Volunteering as Haematopoietic Stem Cell (HSC) Donors", 
        "overall_contact": {
            "email": "h.boenig@blutspende.de", 
            "last_name": "Halvard Boenig, M.D. Ph.D", 
            "phone": "+49-69-6782177"
        }, 
        "overall_official": {
            "affiliation": "German Red Cross Blood Service and Institute for Transfusion Medicine and Immunohematology of the Goethe University, Frankfurt, Germany", 
            "last_name": "Halvard Boenig, M.D. Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety as measured by the incidence, type and severity of adverse events.", 
            "measure": "Safety of single ascending doses of POL6326 by intravenous infusion according to standard criteria", 
            "safety_issue": "Yes", 
            "time_frame": "2 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841476"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the pharmacokinetic profile of POL6326 following single intravenous administration, e.g. Cmax, AUC, terminal half life and clearance", 
                "measure": "Pharmacokinetic outcome", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "description": "Time dependent measurement of CD34+ cells during and after infusion of POL6326 in all subjects", 
                "measure": "Mobilisation of CD34+ cells", 
                "safety_issue": "No", 
                "time_frame": "2 days"
            }
        ], 
        "source": "Polyphor Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Polyphor Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}